For
the quarter ending sept 2022, consolidated net sales (including other operating income) of Dr Lal Pathlabs has increased 7.10% to Rs 533.8 crore compared to quarter ended sept 2021. Operating profit margin has declined from 28.39% to 26.94%, leading to 1.63% rise in operating profit to Rs 143.80 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 24.96% to 21.77%. Employee cost increased from 16.77% to 17.03%. Other expenses rose from 29.88% to 34.26%. Selling and administration expenses fell from 14.02% to 13.92%. Other income fell 39.16% to Rs 8.7 crore. PBIDT fell 2.12% to Rs 152.5 crore. Provision for interest rose 131.91% to Rs 10.9 crore. Loan funds rose to Rs 285.40 crore as of 30 September 2022 from Rs 41.40 crore as of 30 September 2021. Inventories declined from Rs 55.20 crore as of 30 September 2021 to Rs 54.50 crore as of 30 September 2022. Sundry debtors were higher at Rs 91.80 crore as of 30 September 2022 compared to Rs 67.30 crore as of 30 September 2021. Cash and bank balance declined from Rs 997.80 crore as of 30 September 2021 to Rs 525.90 crore as of 30 September 2022. Investments declined from Rs 128.00 crore as of 30 September 2021 to Rs 123.90 crore as of 30 September 2022.
PBDT fell 6.29% to Rs 141.6 crore. Provision for depreciation rose 89.27% to Rs 38.8 crore. Fixed assets increased to Rs 805.20 crore as of 30 September 2022 from Rs 325.60 crore as of 30 September 2021. Intangible assets increased from Rs 141.00 crore to Rs 554.70 crore.
Profit before tax down 21.29% to Rs 102.80 crore. Share of profit/loss were nil in both the periods. Provision for tax was expense of Rs 30.4 crore, compared to Rs 34.3 crore. Effective tax rate was 29.57% compared to 26.26%.
Minority interest decreased 46.15% to Rs 0.70 crore. Net profit attributable to owners of the company decreased 24.53% to Rs 71.70 crore. Equity capital increased from Rs 83.30 crore as of 30 September 2021 to Rs 83.40 crore as of 30 September 2022. Per share face Value remained same at Rs 10.00.
Promoters’ stake was 55.05% as of 30 September 2022 ,compared to 55.23% as of 30 September 2021 .
For year-to-date (YTD) results analysis.
Net sales (including other operating income) of Dr Lal Pathlabs has declined 6.20% to Rs 1036.5 crore.
Operating profit margin has declined from 29.91% to 25.21%, leading to 20.94% decline in operating profit to Rs 261.30 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 24.39% to 22.23%. Employee cost increased from 15.38% to 18.11%. Other expenses rose from 30.32% to 34.45%. Selling and administration expenses fell from 14.66% to 13.88%. Other income fell 40.14% to Rs 17 crore. PBIDT fell 22.46% to Rs 278.3 crore. Provision for interest rose 108.60% to Rs 19.4 crore. Loan funds rose to Rs 285.40 crore as of 30 September 2022 from Rs 41.40 crore as of 30 September 2021. Inventories declined from Rs 55.20 crore as of 30 September 2021 to Rs 54.50 crore as of 30 September 2022. Sundry debtors were higher at Rs 91.80 crore as of 30 September 2022 compared to Rs 67.30 crore as of 30 September 2021. Cash and bank balance declined from Rs 997.80 crore as of 30 September 2021 to Rs 525.90 crore as of 30 September 2022. Investments declined from Rs 128.00 crore as of 30 September 2021 to Rs 123.90 crore as of 30 September 2022.
PBDT fell 25.94% to Rs 258.9 crore. Provision for depreciation rose 88.16% to Rs 74.7 crore. Fixed assets increased to Rs 805.20 crore as of 30 September 2022 from Rs 325.60 crore as of 30 September 2021. Intangible assets increased from Rs 141.00 crore to Rs 554.70 crore.
Profit before tax down 40.56% to Rs 184.20 crore. Share of profit/loss were nil in both the periods. Provision for tax was expense of Rs 53.6 crore, compared to Rs 79.9 crore. Effective tax rate was 29.10% compared to 25.78%.Minority interest decreased 68.42% to Rs 1.20 crore. Net profit attributable to owners of the company decreased 42.79% to Rs 129.40 crore.
Equity capital increased from Rs 83.30 crore as of 30 September 2021 to Rs 83.40 crore as of 30 September 2022. Per share face Value remained same at Rs 10.00.
Promoters’ stake was 55.05% as of 30 September 2022 ,compared to 55.23% as of 30 September 2021 .
Full year results analysis.
Net sales (including other operating income) of Dr Lal Pathlabs has increased 32.01% to Rs 2087.4 crore. Operating profit margin has declined from 27.59% to 26.86%, leading to 28.51% rise in operating profit to Rs 560.70 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 25.12% to 24.06%. Employee cost increased from 17.31% to 17.48%. Other expenses rose from 29.98% to 31.59%. Selling and administration expenses rose from 12.92% to 13.63%. Other income rose 2.34% to Rs 52.5 crore. PBIDT rose 25.76% to Rs 613.2 crore. Provision for interest rose 88.75% to Rs 30.2 crore. Loan funds rose to Rs 393.80 crore as of 31 March 2022 from Rs 40.30 crore as of 31 March 2021. Inventories rose to Rs 52.40 crore as of 31 March 2022 from Rs 42.60 crore as of 31 March 2021. Sundry debtors were higher at Rs 85.40 crore as of 31 March 2022 compared to Rs 66.70 crore as of 31 March 2021. Cash and bank balance declined from Rs 926.00 crore as of 31 March 2021 to Rs 617.60 crore as of 31 March 2022. Investments rose to Rs 65.50 crore as of 31 March 2022 from Rs 59.30 crore as of 31 March 2021 .
PBDT rose 23.62% to Rs 583 crore. Provision for depreciation rose 40.03% to Rs 108.1 crore. Fixed assets increased to Rs 840.40 crore as of 31 March 2022 from Rs 371.50 crore as of 31 March 2021. Intangible assets increased from Rs 85.40 crore to Rs 549.90 crore.
Profit before tax grew 20.41% to Rs 474.90 crore. Share of profit/loss were nil in both the periods. Provision for tax was expense of Rs 124.6 crore, compared to Rs 97.9 crore. Effective tax rate was 26.24% compared to 24.82%.
Minority interest increased 12.24% to Rs 5.50 crore. Net profit attributable to owners of the company increased 18.24% to Rs 344.80 crore.
Equity capital stood at Rs 83.30 crore as of 31 March 2022 to Rs 83.30 crore as of 31 March 2021. Per share face Value remained same at Rs 10.00.
Promoters’ stake was 55.23% as of 31 March 2022 ,compared to 55.23% as of 31 March 2021 .
Cash flow from operating activities increased to Rs 446.70 crore for year ended March 2022 from Rs 398.20 crore for year ended March 2021. Cash flow used in acquiring fixed assets during the year ended March 2022 stood at Rs 476.10 crore, compared to Rs 59.60 crore during the year ended March 2021.
Other Highlights
Covid and Allied
contributed 3.7% to Revenue in Q2 FY23.
In Q2 FY23, non-COVID
business grew by 14.8% on YoY basis and Covid & Allied business fell by
61.3% on YoY.